A pre revenue company trading at this MC will surely garner some shorting interest.
i think we need to look at the next cohort as the start of P2, which means cu67 is a P2 asset. The next cohort, which is the first multi dose cohort, is dosing the same schedule as their dose expansion (P2).
unless they change their RP2D. Although renal damage may be a key factor in limiting cumulative dose
A pre revenue company trading at this MC will surely garner some...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.23 |
Change
0.560(8.40%) |
Mkt cap ! $2.280B | |||
| Open | High | Low | Value | Volume |
| $6.81 | $7.42 | $6.77 | $85.37M | 11.80M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3000 | $7.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.26 | 72772 | 1 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |